No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) KDM5A Antibodies:
anti-Human KDM5A Antibodies:
anti-Mouse (Murine) KDM5A Antibodies:
Go to our pre-filtered search.
Human Polyclonal KDM5A Primary Antibody for IHC (p), IP - ABIN258184
Tsai, Nguyen, Shi, Barton: p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo. in Molecular and cellular biology 2008
Show all 4 Pubmed References
Human Monoclonal KDM5A Primary Antibody for FACS, IF - ABIN3201015
Christensen, Agger, Cloos, Pasini, Rose, Sennels, Rappsilber, Hansen, Salcini, Helin: RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. in Cell 2007
Show all 3 Pubmed References
Findings indicate the importance of cellular phenotypic heterogeneity in therapeutic resistance and identify lysine demethylase 5A/B (KDM5A/B) as key regulators of this process.
A point mutation in LxCxE motif of KDM5A/RBP2 renders it incapable of 130 kDa retinoblastoma-associated protein (p130)-interaction and hence, repression of E2F transcription factor 4 and (E2F)-regulated gene promoters.
ZEB1 play a crucial role in KDM5A induced function.
both KDM5A and KDM5B are involved in the lengthening of DICER1
RBP2 promotes HIF-1alpha-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
promotes overexpression and activation of BCL2 in acute lymphoblastic leukemia development and progression
Ectopic overexpression of RBP2 can induce cancer stem cell-like (CSC) phenotypes through epithelial to mesenchymal transition in renal cell carcinoma cells by converting them to a more mesenchymal phenotype.
miR-34a promotes the osteogenic differentiation of human adipose-derived stem cells via the RBP2/NOTCH1/CYCLIN D1 coregulatory network.
This study aimed to explore the expression level of RBP2 in hepatocellular carcinoma (HCC) and its prognostic significance.
KDM5A suppresses ovarian cancer cell apoptosis under paclitaxel treatment.
KDM5A 5A inhibitor blocks cancer cell growth and drug resistance
KDM5A-mediated H3K4me3 modification participated in the etiology of osteoporosis and may provide new strategies to improve the clinical efficacy of BMP2 in osteoporotic conditions.
KDM5A demethylates H3K4 to allow ZMYND8-NuRD to operate within damaged chromatin to repair DNA double strand breaks.
the radiation sensitivity observed following depletion of Jarid1A is not caused by a deficiency in repair of DNA double-strand breaks.
Treatment-induced temozolimide resistance in glioblastoma cells involves KDM5A mediated epigenetic mechanisms.
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
KDM5A is regulated by its reader domain through a positive-feedback mechanism
Data indicate that lysine (K)-specific demethylase 5A RBP2 (JARID1A; KDM5A) epigenetically downregulated micrRNA-21 (miR-21) in blast transformation of chronic myeloid leukemia (CML).
LSD1 is a more sensitive molecular marker than RBP2 on thyroid cancer diagnosis.
MiR-212 directly regulates the expression of RBP2 and inhibits cell growth in gastric cancer, which may provide new clues to treatment.
Conditional, systemic ablation of RBP2 in pituitary or thyroid tumor-bearing Rb1(+/-) mice is sufficient to slow tumor growth and significantly extend survival without causing obvious toxicity to the host. These findings show that established Rb1-null tumors require RBP2 for growth.
Kdm5a associates with p50 and binds to the Socs1 promoter region in resting natural killer cells.
Data show that NP23 and NJL belong to a subset of chromatin-modifying fusion oncoproteins causing leukemia.
Maintenance of gene silencing by the coordinate action of the H3K9 methyltransferase G9a/KMT1C and the H3K4 demethylase Jarid1a/KDM5A.
In terminally differentiated cells, common KDM5A and E2F4 gene targets were bound by the pRB-related protein p130, a DREAM complex component.
Study reports that RBP2 is a demethylase that specifically catalyzes demethylation on histone H3 lysine 4, whose methylation is normally associated with transcriptionally active genes.
JARID1a formed a complex with CLOCK-BMAL1 which was recruited to Per2 promoter;it increased histone acetylation by inhibiting histone deacetylase 1 function and enhanced transcription by CLOCK-BMAL1; JARID1a depletion shortened period of circadian rhythms
KDM5A interacts physically with RBP-J
mutation can downregulate cardiac cell proliferation by repressing cyclin D1 expression in the same way as jumonji
A functional interplay between the PRC2 complex and the H3K4me3 demethylase Rbp2 (Jarid1a) in mouse embryonic stem (ES) cells.
The protein encoded by this gene is a ubiquitously expressed nuclear protein. It binds directly, with several other proteins, to retinoblastoma protein which regulates cell proliferation. This protein also interacts with rhombotin-2 which functions distinctly in erythropoiesis and in T-cell leukemogenesis. Rhombotin-2 is thought to either directly affect the activity of the encoded protein or may indirectly modulate the functions of the retinoblastoma protein by binding to this protein.
jumonji, AT rich interactive domain 1A (Rbp2 like)
, lysine-specific demethylase 5A
, jumonji, AT rich interactive domain 1A
, lysine (K)-specific demethylase 5A
, JARID1A variant protein-like
, jumonji AT-rich interactive domain 1A
, retinoblastoma binding protein 2
, Jumonji, AT rich interactive domain 1A (RBP2-like)
, histone demethylase JARID1A
, jumonji/ARID domain-containing protein 1A
, retinoblastoma-binding protein 2